Lotus upgrades facility
Generic drugmaker Lotus Pharmaceuticals Co (美時化學製藥) yesterday announced that it has begun upgrading its manufacturing facility in Nantou County to expand the production of oral oncology products. The upgrade is expected to be completed in five years and cost tens of millions of US dollars, the company said, adding that its board has approved capital expenditure of US$11 million for this year. The Nantou site has been audited by local, US, EU and Japanese regulatory authorities, enabling it to manufacture products for nearly every market in the world, the firm said. In addition to standard solid oral dose manufacturing, the company can produce hormonal products, soft gelatin capsules, and cytotoxic and high-potency molecules, it said.
Health2Sync launches app
Taipei-based Health2Sync (慧康生活科技) yesterday launched HealthPass, an app that grants its users full control of their health data using blockchain technology. The start-up teamed up with Bitmark Inc, a Taipei-based blockchain developer, to register users’ health data as their personal digital property. Users would be able to selectively allow certain companies and services to access their health data as part of a monetization scheme. The start-up has also tapped CTBC Bank (中信銀行) to use the lender’s blockchain-based solution to enable transactions resulting from monetization. With the help of health data analysis, insurers would be able to create tailored products based on each user’s health, the firm said.
Pharmally sales up 20.27%
Pharmally International Holding Co (康友製藥), a maker of large-volume parenteral solutions for vaccines and intravenous medicines, yesterday announced that net income last year rose 17.44 percent year-on-year to NT$1.1 billion (US$35.59 million), or earnings per share of NT$14.29, while sales rose 20.27 percent to NT$5.18 billion. Pharmally shares closed unchanged at NT$214 in Taipei trading yesterday. The shares last year saw a spike in volatility, surging to more than NT$500 on progress made at its Indonesian poultry vaccine production plant, before falling below NT$140 after a filing revealed that company officials were trimming their holdings.
Pegatron revenue slumps
Pegatron Corp (和碩) on Monday reported that revenue last month dropped 33.4 percent month-on-month, but rose 6.2 percent year-on-year to NT$81.65 billion. Revenue in the first two months rose 3.2 percent year-on-year to NT$204.28 billion, it said. The Jakarta Post reported that Pegatron’s new plant in Indonesia is expected to begin operations next month. Separately, Lite-On Technology Corp (光寶科技) on Monday reported that revenue last month declined 30.33 percent month-on-month and 16.6 percent year-on-year to NT$10.87 billion. Revenue in the first two months also fell 10.36 percent to NT$26.48 billion.
Chungwa Picture shares fall
A plan to lay off 2,500 employees sent shares in Chunghwa Picture Tubes Ltd (華映) into a tailspin yesterday, dealers said. The heavy selling emerged after the Taiwan Stock Exchange said that the financially troubled panel maker, which has filed for bankruptcy protection, would have to delist regardless of whether the restructuring plan is approved by the courts. Shares fell by the daily limit of 10 percent to close at NT$0.54.
The rise of the cryptocurrency dogecoin has reached a new level after the token was used to pay for a lunar satellite launch. SpaceX, Elon Musk’s commercial rocket firm, is to embark on a moon voyage next year carrying a so-called cubesat — a mini-satellite used for space research — from Geometric Energy Corp that has been paid for entirely in dogecoin. The development is the latest twist in the saga over the digital token, which started as a joke in 2013, but is now a dominating Internet meme and sitting on a 21,000 percent rally in the past year. Musk has
The Financial Supervisory Commission (FSC) yesterday fined Citibank Taiwan Ltd (花旗台灣) NT$10 million (US$357,194) and DBS Bank Taiwan (星展台灣) NT$6 million for breaches of the nation’s anti-money laundering (AML) regulations. The NT$10 million fine is the highest penalty that it has imposed on a domestic bank, the commission said. Citibank Taiwan failed to set up a sound mechanism for evaluating clients’ risk of money laundering and for detecting suspicious transactions, Banking Bureau Deputy Director-General Huang Kuang-hsi (黃光熙) told a news conference in New Taipei City. The bank based its AML policies on those of its US-based parent company, Citigroup Inc, but the policies
CAPACITY EXPANSION: Construction of the site, which is to be the firm’s first mRNA production facility outside of Europe, is to begin this year and likely finish in 2023 COVID-19 vaccine maker BioNTech SE yesterday said it would build a Southeast Asia headquarters and manufacturing site in Singapore to produce hundreds of millions of messenger RNA (mRNA)-based vaccines per year. Construction of the site would start this year, and it could become operational by 2023, the German company said in a statement. “With this planned mRNA production facility, we will increase our overall network capacity, and expand our ability to manufacture and deliver our mRNA vaccines and therapies to people around the world,” BioNTech chief executive Ugur Sahin said. The vaccine produced by BioNTech jointly with Pfizer Inc of
OUTBREAK: About 200 of the airline’s 1,200 pilots are not able to work. Most of them have been quarantined to prevent further infection, but 12 have COVID-19 China Airlines Ltd (CAL,中華航空) yesterday confirmed that it would temporarily reduce its cargo flight services to cope with a pilot shortage, as one-sixth of its pilots have been sidelined by a COVID-19 outbreak. “We are working out a new schedule,” the airline said in a statement after local news media reports on Saturday said that it would be reducing its cargo services from Wednesday, primarily affecting US destinations. CAL declined to give details about its new operating plan, but the reports said that it would be suspending its cargo flights to Dallas Fort Worth International Airport, Hartsfield-Jackson Atlanta International Airport and